Masayoshi Masuko

Masayoshi Masuko

Auto-generated profile, based on publicly available information

Masayoshi Masuko

Department of Hematopoietic Cell Transplantation, Niigata University Medical and Dental Hospital, Niigata, Japan

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
MYMasahide Yamamoto
Masahide Yamamoto
MSMaho Sato
Maho Sato
YOYasushi Onishi
Yasushi Onishi
YSYoji Sasahara
Yoji Sasahara
HSHideki Sano
Hideki Sano
Ayako AraiAyako Arai
Ayako Arai

15 July 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
KFKyoko Fuse
Kyoko Fuse
SUShun Uemura
Shun Uemura
STSuguru Tamura
Suguru Tamura
TSTatsuya Suwabe
Tatsuya Suwabe
TKTakayuki Katagiri
Takayuki Katagiri
MMMasayoshi Masuko
Masayoshi Masuko
Although allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is a curative therapy for high‐risk acute leukemia (AL), some patients still relapse. Since patients simultaneously have many prognostic factors, difficulties are associated with the construction of a patient‐based prediction algorithm of relapse. The alternating decision tree (ADTree) is a successful classification method that combines decision trees with the predictive accuracy of boosting. It is a component of machine learning (ML) and has the capacity to simultaneously analyze multiple factors. Using ADTree, we attempted to construct a prediction model of leukemia relapse within 1 year of transplantation. With the model of training data (n = 148), prediction accuracy, the AUC of ROC, and the κ‐statistic value were 78.4%, 0.746, and 0.508, respectively. The false positive rate (FPR) of the relapse prediction was as low as 0.134. In an evaluation of the model with validation data (n = 69), prediction accuracy, AUC, and FPR of the relapse prediction were similar at 71.0%, 0.667, and 0.216, respectively. These results suggest that the model is generalized and highly accurate. Furthermore, the output of ADTree may visualize the branch point of treatment. For example, the selection of donor types resulted in different relapse predictions. Therefore, clinicians may change treatment options by referring to the model, thereby improving outcomes. The present results indicate that ML, such as ADTree, will contribute to the decision‐making process in the diversified allo‐HSCT field and be useful for preventing the relapse of leukemia.

1 January 2010 in International Journal of Medical Sciences
Verified
Journal Article
Open access
MNMiwako Narita
Miwako Narita
MMMasayoshi Masuko
Masayoshi Masuko
TKTohri Kurasaki
Tohri Kurasaki
TKToshiki Kitajima
Toshiki Kitajima
STShoko Takenouchi
Shoko Takenouchi
MTMasuhiro Takahashi
Masuhiro Takahashi
Although tyrosine kinase inhibitors is effective for dramatically reducing CML cells, it might be difficult to eradicate completely the CML stem cells. We aimed to clarify the safety and effects of WT1 peptide vaccination in combination with imatinib therapy for a CML patient. A 51 year-old male with CML in CP, who showed a resistance against imatinib therapy for 2.5 years, began to be treated with 9mer modified-type WT1 peptides in combination with standard dose of imatinib. Although every 2-week-administration of WT1 peptides for 22 weeks did not show definite effects on the quantification of bcr-abl transcripts, by changing the administration from every 2 weeks to 4 weeks bcr-abl transcripts decreased remarkably. After 11 months of every 4-week-administration of the peptides and 12 months post cessation of the peptides bcr-abl transcripts achieved to the level below detection by RQ/RT-PCR (complete molecular response). WT1/MHC tetramer+CD8+ CTLs, which appeared after the second administration of WT1 peptides and remained more than 15 in number among 106 CD8+ T cells throughout the administration of WT1 peptides, are still present in the blood on 14th month post cessation of the peptides. An in vitro study as to the cytotoxicity of lymphocytes induced by mixed lymphocyte peptide culture demonstrated that cultured lymphocytes possessed cytotoxicity against WT1 expressing leukemia cells and the cytotoxicity was WT1-specific and MHC class I restricted. The present study showed that WT1 peptide vaccination in combination with TKI is feasible and effective in the therapy for imatinib-resistant CML.

28 March 2011 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
NWN. Watanabe
N. Watanabe
MNM. Narita
M. Narita
TFT. Furukawa
T. Furukawa
TNT. Nakamura
T. Nakamura
AYA. Yamahira
A. Yamahira
MTM. Takahashi
M. Takahashi

1 January 2011 in Internal Medicine
Verified
Journal Article
Open access
PDF file
KKKaori Karimata
Kaori Karimata
MMMasayoshi Masuko
Masayoshi Masuko
Takashi UshikiTakashi Ushiki
Takashi Ushiki
TKTakashi Kozakai
Takashi Kozakai
YSYasuhiko Shibasaki
Yasuhiko Shibasaki
YAYoshifusa Aizawa
Yoshifusa Aizawa
We describe a 60-year-old Japanese patient with chronic myeloid leukemia (CML) who developed myelodysplastic syndrome (MDS) with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment. Most cases that developed chromosomal abnormality in Ph negative cells during imatinib therapy were reported to have less clinical implications, while rare cases developed MDS/AML. The present case suggested that metaphase karyotype analysis and bone marrow examination should be performed for the long term follow-up under imatinib treatment in cases showing cytopenia. The results also suggested that monosomy 7 in Ph negative cells may be an indicator of a poor prognosis.

1 October 2007 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
KOKiyoshi Okazuka
Kiyoshi Okazuka
MMMasayoshi Masuko
Masayoshi Masuko
YSYoshinobu Seki
Yoshinobu Seki
HHHitomi Hama
Hitomi Hama
NHNoriyuki Honma
Noriyuki Honma
YAYoshifusa Aizawa
Yoshifusa Aizawa
Acute promyelocytic leukemia (APL) is characterized by a reciprocal chromosomal translocation involving the gene for retinoic acid receptor α (RAR). Most APL patients have a t(15;17) translocation that generates the PML-RAR fusion gene, and such patients respond well to treatment with all-trans retinoic acid (ATRA). Some APL cases also involve rearrangements that fuse RAR to partner genes other than PML, including nucleophosmin (NPM), promyelocytic leukemia zinc finger (PLZF), nuclear mitotic apparatus (NUMA), and Stat5b, but the clinical characteristics of APL without PML-RAR have not been fully clarified. We describe a 64-year-old man with NPM-RAR—positive APL who was receiving hemodialysis therapy for chronic uremia. Complete remission was achieved with ATRA monotherapy and was maintained for 18 months with consolidation chemotherapy. These findings suggest that ATRA can be used to treat APL patients with NPM/RAR as well as APL with PML/RAR.